Clinical trials: Gastrointestinal Tract
Roux-en-Y Bariatric Surgery
Investigation of the Effects of Obesity Surgery on Appetitive Behaviour
Among all the existing ways to treat obesity (lifestyle, pharmacological), Roux-en-Y gastric bypass (RYGB) surgery is currently the most effective.
- Trial name
- NCT02010385
- Testing
- Octreotide, Saline
- Where
- Ireland
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- University College Dublin
Obsessive-Compulsive Disorder, Tic Disorder
Pathogenesis of Pediatric Obsessive-compulsive Disorder: Based on the Microbiota-gut-brain Axis
This study aims to investigate the characteristics of the microbiota-gut-brain axis in pediatric patients with obsessive-compulsive disorder (OCD) through performing an integrated analysis of gut microbiota, serum metabolomics…
- Trial name
- NCT06754319
- Where
- China
- Volunteers
- 125 people, healthy volunteers welcome
- Sponsor
- Shanghai Mental Health Center
Overweight and Obesity
Satiety Innovation- Study 793. University of Aberdeen
The proposed study will address the effect of developed novel food products through processing innovation on motivation to eat, biomarkers of satiety, nutrient bioavailability and gut health using in vivo studies and validating…
- Trial name
- SATIN (NCT01724411)
- Testing
- Resistant Starch type 3
- Where
- United Kingdom
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- P Burns
Cholestasis
Sincalide (Cholecystokinin Octapeptide) Versus Placebo in Neonates at High Risk for Developing Parenteral Nutrition Associated Cholestasis
OBJECTIVES: I. Compare conjugated bilirubin levels and serum bile acid levels in severely premature newborns on long term parenteral nutrition and given either sincalide or placebo. II.
- Trial name
- NCT00004414
- Testing
- sincalide
- Where
- 6 sites in United States
- Volunteers
- 252 people
- Sponsor
- University of Michigan
Helicobacter Pylori Infection, Gut Microbiota
Effect of Probiotics on Gut Microbiota During the Helicobacter Pylori Eradication
Helicobacter pylori (H. pylori) is still infecting more than half of the population in many countries, although the prevalence is decreasing. As a main cause of chronic gastritis, peptic ulcer, and malignant gastric tumors, H.
- Trial name
- NCT05662514
- Testing
- Bifidobacterium animalis subsp. lactis BLa80
- Volunteers
- 100 people
- Sponsor
- Qilu Hospital of Shandong University
Head and Neck Carcinoma, Adenoid Cystic Carcinoma
VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
This is a multicenter, open-label, Phase 1/2 study of orally administered VMD-928 monotherapy and in combination with pembrolizumab in adult subjects with advanced solid tumors or lymphoma that have progressed or are non…
- Conditions
- Head and Neck Carcinoma, Adenoid Cystic Carcinoma, Lung Cancer, Non-Small Cell Lung Cancer
- Trial name
- NCT03556228
- Testing
- VMD-928 100 mg Tablet, VMD-928 Tablet and Pembrolizumab (200 mg)
- Where
- 15 sites in United States, Puerto Rico
- Volunteers
- 242 people
- Sponsor
- VM Oncology, LLC
Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency
Phase 4, Double-blind Study Evaluating the Response on Computed Tomography (CT) Lung Density Decline Rates of Respreeza / Zemaira Weekly for 3 Years in Adults With alpha1 Antitrypsin Deficiency (AATD)
This is a multicenter, parallel-group, double-blind, randomized phase 4 study designed to identify the optimal dose of CE1226 (2 active doses) to slow disease progression as assessed by reduced rates of annual lung density…
- Conditions
- Alpha1 Antitrypsin Deficiency, Alpha1-Proteinase Inhibitor Deficiency, Emphysema
- Trial name
- NCT07326592
- Testing
- CE1226
- Where
- 2 sites in Denmark
- Volunteers
- 270 people
- Sponsor
- CSL Behring
Cystic Fibrosis
A Phase 3 Study of VX-445 Combination Therapy in Subjects With Cystic Fibrosis Heterozygous for the F508del Mutation and a Minimal Function Mutation (F/MF)
This study will evaluate the efficacy of VX-445 in triple combination (TC) with tezacaftor (TEZ) and ivacaftor (IVA) in subjects with cystic fibrosis (CF) who are heterozygous for F508del and a minimal function mutation (F/MF…
- Trial name
- NCT03525444
- Testing
- VX-445/TEZ/IVA, IVA
- Where
- 115 sites in United States, Australia and 11 more
- Volunteers
- 405 people
- Sponsor
- Vertex Pharmaceuticals Incorporated
Type 2 Diabetes
Efficacy of Acarbose on Intestinal Microbiome and Incretins of Type 2 Diabetes
This study is aimed to investigate the effect of acarbose on intestinal microbiome and incretins, therefore to explore the new pathways or new targets to treat type 2 diabetes.
- Trial name
- NCT01758471
- Testing
- Glipizide, Acarbose
- Where
- China
- Volunteers
- 160 people, healthy volunteers welcome
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma
Evaluation of [18F]AlF-NOTA-PCP2 PET/CT for PD-L1 Detection in Malignant Tumors
This phase I/II clinical trial evaluates the safety, efficacy, and prognostic potential of [18F]AlF-NOTA-PCP2 PET/CT imaging in assessing PD-L1 expression in malignant tumors, including glioblastoma, head and neck squamous cell…
- Conditions
- Glioblastoma (GBM), Head and Neck Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Esophageal Cancer
- Trial name
- PD-L1-PET (NCT06690216)
- Testing
- PET/CT （[18F]AlF-NOTA-PCP2）, [18F]AlF-NOTA-PCP2 PET/CT Imaging for PD-L1 Expression in Malignant Tumors
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Man Hu
Cystic Fibrosis
Coping Compliance and Adjustment in Adolescents With Cystic Fibrosis
In this research, we will use established surveys to look at the relationship between various styles of coping with a disease, religious coping styles, treatment compliance, locus of control, broad measures of mental health and…
- Trial name
- NCT00577252
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Akron Children's Hospital
Cystic Fibrosis
Developing and Validating a Patient-reported Outcome Instrument to Monitor Symptom Management in Pulmonary Exacerbation in CF
The aim of this study is to develop a reliable and valid instrument to measure symptom management (experience and / or management strategies) during exacerbation episodes in CF patients.
- Trial name
- NCT02464267
- Where
- Switzerland
- Volunteers
- 18 people
- Sponsor
- University of Zurich
Neurogenic Bladder, Neurogenic Bowel
Sacral Neuromodulation in Neurogenic Patients
The goal of this observational study is to evaluate efficacy and safety of sacral neuromodulation in neurogenic patients compared to non-neurogenic (idiopathic) patients. [.
- Conditions
- Neurogenic Bladder, Neurogenic Bowel, Urge Incontinence, Overactive Bladder
- Trial name
- NCT05688644
- Testing
- InterStim II
- Where
- Israel
- Volunteers
- 100 people
- Sponsor
- Omri Schwarztuch Gildor
Non-alcoholic Fatty Liver Disease
Prospective Cohort Assessing the Role of the Genotoxin Colibactin From Escherichia Coli B2 in the Genesis of NASH
In a population of patients with Non Alcoholic Fatty Liver Disease (NAFLD), the investigators will compare the composition of the gut microbiota from patients with simple steatosis with that with steatohepatitis.
- Trial name
- Coli-NASH (NCT02390232)
- Testing
- liver biopsy, collection of stools, blood sample
- Where
- France
- Volunteers
- 176 people
- Sponsor
- University Hospital, Toulouse
Neoplasms, Carcinoma, Non-Small-Cell Lung
A Study of mRNA-5671/V941 as Monotherapy and in Combination With Pembrolizumab (V941-001)
This study will determine the safety and tolerability and establish a preliminary recommended Phase 2 dose of V941(mRNA-5671/V941) as a monotherapy and in combination with pembrolizumab infusion.
- Conditions
- Neoplasms, Carcinoma, Non-Small-Cell Lung, Pancreatic Neoplasms, Colorectal Neoplasms
- Trial name
- NCT03948763
- Testing
- V941, Pembrolizumab
- Where
- 26 sites in United States, Australia and 5 more
- Volunteers
- 70 people
- Sponsor
- Merck Sharp & Dohme LLC
Primary Biliary Cirrhosis
Efficacy and Safety of Fenofibrate Combined With UDCA in PBC Patients With an Incomplete Biochemical Response to UDCA
The purpose of this protocol is to conduct a trial in a selected population of patients with PBC based on an incomplete biochemical response after 12 months of UDCA therapy.
- Trial name
- NCT02965911
- Testing
- Fenofibrate, UDCA
- Where
- China
- Sponsor
- Beijing 302 Hospital
Severe Acute Malnutrition
Ready to Use Therapeutic Food (RUTF) in Severe Malnourished Children
1. RUTF would be more effective (quicker catch-up growth by promoting more tissue accrue resulting decrease stay in rehabilitation ward) in treating children with SAM during the rehabilitation phase than khichuri /halwa; 2.
- Trial name
- RUTF (NCT01331044)
- Testing
- Plumpy Nut, Khichuri and Halwa
- Where
- Bangladesh
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- International Centre for Diarrhoeal Disease Research, Bangladesh
Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer
MEDI4736 (Durvalumab) in Patients With Brain Metastasis From Epithelial-derived Tumors
Brain metastases are the most common intracranial malignancy occurring in 20-40% of all cancers, and the presence of CNS metastases is associated with a poor prognosis.
- Conditions
- Non-Small Cell Lung Cancer, Nonsmall Cell Lung Cancer, Breast Cancer, Cancer of Breast
- Trial name
- NCT02669914
- Testing
- MEDI4736
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Washington University School of Medicine
Non-Alcoholic Fatty Liver Disease
Effects of TOTUM-448 on Liver Fat Content, Cardiometabolic Risk Factors and Gut Microbiota Among Participants with MASLD
This clinical trial aims to investigate the effects of TOTUM-448, a mix of 5 plant extracts and choline, consumed at the daily regimen of two times per day, on liver fat content, cardiometabolic risk factors and gut microbiota…
- Trial name
- CARDIO-LIVER (NCT06704321)
- Testing
- TOTUM-448
- Where
- Canada
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Valbiotis
Gastrointestinal Dysfunction
Phage 3Determination of Phage/Probiotic Synergistic Effects on Gastrointestinal Health
The goal of this double blinded clinical trial is to determine whether consumption of the PreforPro product, when co-consumed with Bacillus subtilis DE111 probiotic, synergistically improves bowel regularity, perceived physical…
- Trial name
- NCT05750433
- Testing
- PreforPro+B. subtilis DE111 probiotics, B. subtilis DE111
- Where
- United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Colorado State University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.